ArticleFrontiers in genetics2025
Constructing a novel mitochondrial-related gene signature for predicting survival and evaluating the tumor immune microenvironment in clear cell renal cell carcinoma.
Article in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mitochondria play an important role in tumors. Cellular energy supply, signaling, metabolism, autophagy, aging, and tumorigenesis are all associated with mitochondria. However, we lack a reliable prognostic model using mitochondrial-related genes in clear cell renal cell carcinoma (ccRCC). Methods: A systematic analysis of available TCGA databases and related studies was conducted using the R language and online analysis tools to evaluate the prognostic value of mitochondrial-related genes and the tumor microenvironment in ccRCC. Results: We constructed a novel mitochondrial-related gene signature for predicting survival and evaluating the tumor immune microenvironment in ccRCC. The mitochondrial-related gene signature included MICALL2, FKBP10, and ACADSB. According to the risk score of the risk model, ccRCC patients were divided into high- or low-risk groups. The ccRCC high-risk group with a high-risk score is related to poor prognosis and poor efficacy from immune checkpoint inhibitors (ICIs). Conclusion: Our mitochondrial-related gene signature, as a risk model, could be a reliable ccRCC prognostic biomarker and could predict the response to immunotherapy. The risk score was correlated with the tumor microenvironment and immune cell infiltration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.